As British Columbians were starting to get COVID-19 vaccinations in December 2020 and the first half of 2021, health officials were behind-the-scenes carefully tracking serious side-effects from the shots, according to documents recently released under the Freedom of Information Act.
Although the 42-page released contains few examples of severe reactions, those that were flagged sparked immediate responses from health leaders who were monitoring the millions of Canadians getting the new vaccinations.
Johnson & Johnson
Browse the articles related to this topic below.
Join our community on Guilded.
FDA officials said in a statement that they decided to restrict Johnson & Johnson’s vaccine after taking another look at data on the risk of life-threatening blood clots within two weeks of vaccination.
[Ms. Spit] is part of a very small, little-discussed community of pandemic victims: those who have suffered—or had family or loved ones suffer—from rare but serious vaccine side effects recognized by doctors, regulators and researchers. They say they feel lost in wider Covid-19 statistics, which have shown vaccines to be extremely safe and effective for most of the population.
Faced with the gravest health crisis in memory, governments deployed newly developed vaccines in record time. Many countries indemnified pharmaceutical companies that made the shots, with some governments promising to consider compensation for suspected Covid-19 vaccine-related injuries.
Now governments, including the U.S. and U.K., are trying to live up to that pledge. They are in the very early stages of applying existing vaccine-injury programs to hundreds of claims of injury alleged from Covid-19 shots.
…The U.K.’s National Health Service has received more than 720 claims requesting Covid-19 vaccine-related compensation. The country’s vaccine-injury compensation program entails a one-size-fits-all cash payment of £120,000, equivalent to around $163,000. The volume of Covid-related claims has grown by about 20 a week, toward a projected 1,500 to 1,800 new claims this year, according to U.K. government projections.
http://archive.today/2022.02.22-001537/https://www.wsj.com/articles/covid-19-vaccines-were-deadly-in-rare-cases-governments-are-now-weighing-compensation-11645266603
An investigation of data found in the USA’s Vaccine Adverse Event Reporting System (VAERS) has revealed that extremely high numbers of adverse reactions and deaths have been reported against specific lot numbers of the Covid-19 vaccines several times, meaning deadly batches of the experimental injections have now been identified.
Now, Craig-Paardekooper has created an online app that we have chosen to host at The Expose, allowing you to search for the batch code of Covid-19 vaccine that you received (or any batch code) and see how many deaths, adverse reactions, disabilities and hospitalisations are associated with that code.
In the wake of federal vaccine mandates in the U.S., debate has erupted over the waves of fire fighters,police staff, and other workers who have applied for religious exemptions to getting their COVID-19 shots. The number of applications is likely to spike as the January 4 vaccination deadline nears for large private businesses and some healthcare facilities. And one common reason people give for religious exemptions is the link between vaccines and human fetal cells.
It’s true that such cells have been used either in the testing or development and production of COVID-19 vaccines. The cells are grown in a laboratory and were derived from a few elective abortions performed more than three decades ago. These same cell lines are also used to test and advance our understanding of several routine drugs, including acetaminophen, ibuprofen, and aspirin, and they continue to be used for treatment research in diseases such as Alzheimer’s and hypertension.
We are plunging headlong into the greatest economic transition in history. We don’t have to speculate about that, either.
Researchers who scoured the records of nearly 800,000 U.S. veterans found that in early March, just as the Delta variant was gaining a toehold across American communities, the three vaccines were roughly equal in their ability to prevent infections.
But over the next six months, that changed dramatically.
By the end of September, Moderna’s two-dose COVID-19 vaccine, measured as 89% effective in March, was only 58% effective.
A new study conducted in one county in Minnesota has found an increased likelihood that citizens who received the Johnson & Johnson’s COVID-19 vaccine were more likely to develop blood clots.
The study by the Mayo Clinic found that recipients of the Johnson & Johnson vaccine, officially designated “Janssen,” in Olmsted County, Minnesota, were about 3.7 times more likely to develop a certain variety of cerebral blood clots. Case numbers taken from February 28 to May 7, 2021, were compared to pre-pandemic levels of the blood clots from January 1, 2001, through December 31, 2015.
In this population-based cohort study, we found that the CVST incidence rate 15 days after Ad26.COV2.S vaccination was significantly higher than the prepandemic rate. However, the higher rate of this rare adverse effect must be considered in the context of the effectiveness of the vaccine in preventing COVID-19 (absolute reduction of severe or critical COVID-19 of 940 per 100 000 PY).
Iceland on Friday suspended the Moderna anti-COVID vaccine, citing the slight increased risks of cardiac inflammation, going further than its Nordic neighbours which simply limited use of the jabs.
…This decision owed to “the increased incidence of myocarditis and pericarditis after vaccination with the Moderna vaccine, as well as with vaccination using Pfizer/BioNTech,” the chief epidemiologist said in a statement.
https://medicalxpress.com/news/2021-10-iceland-halts-moderna-jabs-heart-inflammation.html
Peter McCullough, MD, MPH speaks at the 78th Annual Meeting of AAPS on October 2, 2021.
Presentation notes:
- 1min: Something was going very wrong very early in 2019.
- 2m: The threshold for shutting down a new biologic product is just a few cases.
- 3m: Covid-19 was going to be the showcase of what we could do for biotech.
- 5m: The spike protein created by the new Covid-19 is a deadly protein.
- 11m: Our institutions are all culpable in medical malfeasance.
- 13m: We have the biggest biological catastrophe on our hands with a medicinal product in human history…and no-one knows how to stop it.
- List of risk
- 14m: 86% of deaths have no other explanation other than the vaccines.
- 20m: We are in freefall into a lawless state. The Vaccines are not safe for use on either side of the Atlantic. It’s clear that this first generation of [Covid-19] vaccines is not safe.
- 22m: The FDA did not approve Pfizer. The gave a continuation of the emergency use authorization and then conditionally approved Comirnaty with BioNTech which is legally and potentially medicinally distinct. The Pfizer approval is a false talking point.
- 23m: When Pfizer came up for boosters, McCullough and his team presented at the FDA showing that death with the vaccine is greater than death just taking your chances with the infection. The vaccines aren’t safe across the board and the panel agreed 16:2 against the booster.
- 26m: Data for the efficacy of the vaccines do not take into account the Delta variant. These vaccines have failed against Delta and other variants. Two-thirds who get sick with Delta are fully vaccinated. Data shows that the vaccines can’t stop transmission.
- 27m: Effectiveness for Pfizer is at 42%. A vaccine that falls below 50% protection and can’t last a year is not a viable product. Pfizer has failed as a commercial product.
- 29m: The CDC was telling us in May 2021 that the vaccines were failing. They started to do asymmetric reporting to craft a narrative that this was going to be a crisis of the unvaccinated but the CDC data showed the opposite. The ineptitude and willful misconduct of the people running our public health agencies is astounding.
- 32m: The ‘99% of hospitalized were unvaccinated’ message was a propagandized false talking point because the data is not there.
- 33m: The vaccines have had zero impact on the epidemic curve. Mortality is a function of treatment.
- 34m: Many experts have been warning that we shouldn’t vaccinate into a pandemic because it creates resistance. As soon as we started vaccinating, the number of strains starting falling. The virus was figuring out how to thrive in the vaccinated.
- 36m: The Delta variant has achieved antigenic escape. The data shows that the vaccinated is an equal threat to the unvaccinated.
- 38m: Early home treatment is the only thing that makes sense. That’s what it should have always been.
- 40m: Doctors at my institution cannot look me in the eye because they are so ashamed of what they’ve done during the course of this pandemic.
- 44m: If you look through the clinical records [of those who have died] and I will tell you they were all inadequately treated.
- 50m: Natural immunity is superior to vaccine immunity. If we vaccinate people who are covid-recovered, we harm them considerably. The only backstop is natural immunity.
File download:
A Guide to Home-Based COVID Treatment from the Association of American Physicians and Surgeons – PDF (1.4MiB)
Slides:
Backup mirrors:
Some parents are now questioning if Israel moved too fast in jabbing their children. And several health professionals and politicians are demanding the abolition of a policy expected to go into effect next month, which states that the Green Pass will be given only to those who receive a third dose of the vaccine six months after getting a second vaccination.
Whitney Webb is interviewed by the Investigative Corona Committee Germany about who is influencing the conversation around COVID-19. Her interview starts at 1h09m.
Interview notes:
- Google Ventures’ investment in the AstraZeneca vaccine via Vaccitech.
- Reworking of the healthcare system and replacement of doctors with artificial intelligence.
- The ties between government, Big Tech, the military, healthcare and artificial intelligence.
- The AstraZeneca-Oxford vaccine is not non-profit. The two developers at the Jenner Institute, Sarah Gilbert and Adrian Hill, have a company, Vaccitech, on which the technology is based.
- The British Government has directly invested in Vaccitech and is expected a profit.
- The other main stakeholder is Bravos Capital (through Oxford Science Innovation), which was set up by former head of Global Equity Trading at Deutsche Bank.
- The German Government has invested money in CureVac BioNTech vaccine. 20% of the shares is owned by the German Government.
- Sequoia Capital‘s Chinese Branch, Fosun Pharma and The Wellcome Trust (through Oxford Science Innovation) are also investors in Vaccitech.
- The Wellcome Trust is the institution that is most involved in the AstraZeneca vaccine.
- The Jenner Institute is conducting trials in Africa for a universal malaria vaccine and they have a nasty track-record of not being honest about their trials. They lied about risks and infants died.
- The Jenner Institute was a public-private partnership with GlaxoSmithKline and the UK Government in the 1990s. They are one of the main vehicles at Oxford University for vaccine development and also UK vaccine funding research.
- Adrian Hill, the head of the Jenner Institute, is the chief at the UK Government’s UK Vaccine Network which decides which technology to research, fund and give to the population both in the UK and globally through vaccine philanthropy.
- COVAX, The Bill & Melinda Gates Foundation effort to vaccinate the developing world, relies almost entirely on AstraZeneca.
- Johnson & Johnson is being manufactured by Emergent BioSolutions which previously was called BioPort.
- BioPort was a spin-off of a fusion between Porton Down, the UK’s bio-defence lab (Defence Science and Technology Laboratory), and the between [William_J._Crowe] the former head of the Joint Chiefs of Staff under US President Ronald Regan.
- Emergent BioSolutions/BioPort was chosen to manufacture the Johnson & Johnson vaccine despite many scandals.
- The person in-charge of quality control for the Johnson & Johnson vaccine has no experience in the field. His background is head of Military Intelligence teams for the US Military in Iraq and Afghanistan and is also an expert on Iran and North Korea.
- Emergent BioSolutions are intimately connected to the CIA and Bechtel Corporation which has ties to the anthrax attacks in the US.
- Dr. Wodarg raised the possibility that the current situation is being used to covertly study wide use mRNA vaccines.
- Pfizer and Moderna mRNA technology was started with significant investment from DARPA in 2013.
- In 2016, Moderna was the most highly valued biotech company in the US but had no products.
- Regina Dugan greenlighted the investments from DARPA and later left in 2012 to create a DARPA-equivalent for Google and Facebook. She has now teamed up with the Wellcome Trust to create a ‘global health DARPA-equivalent’.
- Some discussion on the pre-911 anthrax vaccine and anthrax attack scandal, with links to reporter Judith Miller who was later involved in the Dark Winter simulation in June 2001.
- A lot of the same people who produced the Dark Winter simulation are the same people who oversaw Event 201 simulation.
- Dr. Wodarg raised concerns about the experimentation with lipid nanoparticles.
- There is a clear push to ‘remake healthcare’ from Silicon Valley towards AI healthcare and Precision Medicine, which is medications, vaccines and gene therapy targeted to the individual.
- A lot of COVID-19 testing in the Western US has been done by Google subsidiary Verily Life Sciences.
- AI healthcare and Precision Medicine is being co-developed by Google and the US military’s Defense Innovation Unit.
- Dr. Wodarg observed that we are seeing the unveiling of a long developed strategy.
- The push in medicine for gene editing goes back to Julian Huxley, first Director General of UNESCO and former president of the British Eugenics Society (renamed in 1989 to the Galton Institute). Julian Huxley, brother of Aldous Huxley, said in 1946 that we should, “make the unthinkable thinkable again” and also coined the term Transumanism. He said that gene editing as a eugenics science needed to be applied along with efforts to merge humans with machines in order to create a ‘new human being’. This goes back to 1957.
- Adrian Hill of the AstraZeneca vaccine spoke at the Galton Institute’s 100 Year Anniversary. The Wellcome Trust hosts their archive.
- Julian Huxley’s speech about “making the unthinkable thinkable again” was in connection with the founding of UNESCO.
- The push for Precision Medicine is ultimately about control and eugenics.
- The Obama Administration funded a lot of the Precision Medicine initiatives. The Biden Administration is creating a ‘health DARPA’ which will be led by Eric Lander (who has ties with Jeffrey Epstein).
- Jeffrey Epstein wanted the seed the human race with his own DNA. The scientists Epstein funded are still around. One of them is Harvard genetecist George Church who has openly promoted unethical human experimentation and eugenics.
- The Edge Foundation was operating as a front for Epstein as a way to gain influence in Silicon Valley, science and academia. His main handler is probably the Mega Group. He has ties with Isabelle Maxwell (Gislane Maxwell’s sister) who is a World Economic Forum technology pioneer.
- Bill Gates‘ ties with Epstein looks to go back to the 1990s. A 2001 Evening Standard article claims that Epstein’s main business partners were Leslie Wexner, Donald Trump and Bill Gates. Microsoft as a company may have been compromised by the same intelligence networks that Epstein operated in.
- Yuval Noah Harari: soon there will be an age of digital dictators and humans have been reduced to ‘hackable animals’ through technology.
- Klaus Schwab openly talks about COVID-19 being the catalyst for The Great Reset and Transhumanism. The fear of COVID would give way to the fear of Climate Change and Cyber Pandemic.
Backup mirrors:
Accurate information about the development and production of COVID-19 vaccines is essential, especially because many proposed candidates use newer molecular technologies for production of a viral vaccine. One concern regarding the ethical assessment of viral vaccine candidates is the potential use of abortion-derived cell lines in the development, production or testing of a vaccine. This analysis utilizes data from the primary scientific literature when available, along with data from clinical trial documents, reputable vaccine tracking websites, and published commercial information.1 It is the hope that by providing accurate data, recipients can make well-informed decisions regarding vaccine choices.
| Analysis of SARS-CoV-2 (COVID-19) Vaccine Candidates
Last Updated 2 June 2021
|
 DOES NOT USE abortion-derived cell line
� Currently undetermined |
||||||
| Sponsor(s)1 | Country | Strategy2 | Clinical Trial Status3 | Public Funding4 | Design & Development | Production | Confirm-atory Lab Tests |
| WHOLE VIRUS VACCINE – LIVE ATTENUATED or INACTIVATED | |||||||
| Beijing Institute of Biological Products/ Sinopharm | China | Inactivated virus
“BBIBP-CorV” Given: Intramuscular 2 doses (3 weeks apart) |
WHO granted Emergency Use Listing (EUL) 7May2021
Early approval in China |
Vero monkey cells Wang et al., Cell 182, P713, 6Aug2020
|
Vero monkey cells Wang et al., Cell 182, P713, 6Aug2020
|
Cytopathic test Vero monkey cells |
|
| Wuhan Institute of Biological Products/ Sinopharm | China | Inactivated virus
“New Crown COVID-19” Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3
Early approval in China |
Vero monkey cells |
Vero monkey cells |
Plaque reduction neutralization test Vero monkey cells Xia et al., JAMA 324, 951, 13Aug2020 |
|
| Bharat Biotech/Indian Council of Medical Research | India | Inactivated virus “BBV152” Given: Intramuscular 2 doses (2 weeks apart) |
India EUA granted |
Vero monkey cells |
Vero monkey cells |
Antibody ELISA Plaque reduction Vero monkey cellsYadav et al., ResearchSquare 10Sept2020 |
|
| Institute of Medical Biology, Chinese Academy of Medical Sciences | China | Inactivated virus “SARS-CoV-2 vaccine” Given: Intramuscular 2 doses (2 weeks apart) |
Phase 3 |
Vero monkey cells |
Vero monkey cells |
Antibody ELISA Neutralizing antibody cytopathic effect Vero monkey cells Pu et al., medRxiv, 6Oct2020 Supplement |
|
| John Paul II Medical Research Institute | USA | Live attenuated virus
|
Pre-clinical |
|
|
� | |
| Research Institute for Biological Safety Problems | Kazakhstan | Inactivated virus
“QazCovid-in” Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3 | � | � | � | |
| Sinovac Biotech Co., Ltd. | China | Inactivated virus
“CoronaVac” Given: Intramuscular 2 doses (2 weeks apart) |
WHO granted Emergency Use Listing (EUL) 1June2021 China granted conditional marketing authorization 8Feb2021 Early approval in China |
Vero monkey cells
|
Vero monkey cells |
protein test HEK293 cells |
|
| Valneva and Dynavax | France USA UK |
Inactivated Virus “VLA2001” plus adjuvant CpG1018 Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3 |
Vero monkey cells
|
Vero monkey cells |
� | |
| VIRAL VECTOR-BASED VACCINE | |||||||
| Altimmune | USA | Replication-deficient
Adenovirus vector “AdCOVID” Given: Intranasal |
Phase 1/2 |
PER.C6 cells |
PER.C6 cells |
|
|
| AstraZeneca
University of Oxford
|
USA
UK |
Replication-deficient
Adenovirus vector “AZD1222” “ChAdOX1nCoV-19” Given: Intramuscular 2 doses (4 weeks apart) |
WHO granted Emergency Use Listing (EUL) on 15Feb2021
India EUA granted |
Operation Warp Speed
HHS-BARDA $1.2 Billion CEPI up to $384 Million |
HEK293 cells |
HEK293 cells |
HEK293 cellsvan Doremalen et al., Nature, 30July2020 MRC-5 cells Almuqrin et al., ResearchSquare 20Oct2020 |
| CanSino Biologics, Inc.
Beijing Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China |
China | Replication-deficient
Adenovirus vector “Ad5-nCoV” Given: Intramuscular 1 dose |
EUA in Chile, Hungary, Pakistan, Mexico |
HEK293 cells |
HEK293 cells |
|
|
| Gamaleya Research Institute | Russia | Replication-deficient
Adenovirus vectors (rAd26-S+rAd5-S) “Gam-COVID-Vac” “Sputnik V” Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3
EUA in 39 countries as of Mar2021 Early approval in Russia August 2020 |
HEK293 cells |
HEK293 cells |
|
|
| ImmunityBio and NantKwest | USA | Replication-deficient Adenovirus vector recombinant “hAd5 S-Fusion + N-ETSD” Given: Subcutaneous |
Phase 1/2 | E.C7 cells (derivative of HEK293 cells) Rice et al., bioRxiv 30July2020 |
E.C7 cells |
Protein and antibody tests HEK293T cells Rice et al., bioRxiv 30July2020 Seiling et al., medRxiv 6Nov2020 |
|
| Institut Pasteur and Themis and Merck | USA
France |
Replication-competent recombinant measles virus
“TMV-083” Given: Intramuscular |
Development Discontinued Phase 1/2Phase 1 |
CEPI up to $4.9 Million | HEK293T
Development and rescue of recombinant measles virus “SARS-CoV-2 S-encoding vaccine candidates… were generated as described previously” |
Vero monkey cells |
Lentiviral vectors for antigenic DCFusogenic testHEK293TFusogenic testS protein expressionVero monkey cellsHörner et al., PNAS 22Dec2020Hörner et al. Supplement |
| Israel Institute for Biological Research (IIBR) | Israel | Replication-competent recombinant vesicular stomatitis virus (VSVΔG) “IIBR-100” Given: Intramuscular1 dose |
Phase 1/2 | BHK hamster cells Vero monkey cells Yahalom-Ronen et al., bioRxiv 19June2020 |
Vero monkey cells Yahalom-Ronen et al., bioRxiv 19June2020 |
Plaque reduction; immunofluorescence Vero monkey cells Yahalom-Ronen et al., bioRxiv 19June2020 |
|
| Janssen Research & Development, Inc.
Johnson & Johnson |
USA | Replication-deficient
Adenovirus vector “Ad26.COV2-S” 1 dose |
FDA Emergency Use Authorization Approved | Operation Warp Speed
HHS-BARDA $1,457,887,081 total |
PER.C6 cells |
PER.C6 cells |
|
| Laboratorio Avi-Mex | Mexico | Live recombinant Newcastle Disease Virus
Expressing spike-fusion chimeric protein “Patria” Given: Intramuscular or Intranasal |
Phase 1 |
Bacterial cells BSRT7 hamster cells |
�
Chicken eggs |
�
Neutralization Assay Vero monkey cells |
|
| Meissa Vaccines, Inc. | USA | Live attenuated recombinant RSV viral vector
“MV-014-210” Given: Intranasal 1-3 doses (5 weeks apart) |
Phase 1 | |
Vero monkey cells Spike expressing, |
� | |
| Rega Institute, KU Leuven | Belgium | Replication-competent attenuated yellow fever vaccine (YF17D) vector
“YF-S0” Given: Intramuscular |
Pre-clinical |
BHK-21J hamster cells |
BHK-21J hamster cells |
Antibody titer Pseudovirus HEK293T cells Immunoblot BHK-21J hamster cells Sanchez-Felipe et al., Nature, 1Dec2020 |
|
| ReiThera | Italy | Replication-deficient simian adenovirus encoding S
“GRAd COV2” Given: Intramuscular 1 dose |
Phase 2/3 |
HEK293T cells Development and rescue of recombinant |
HEK293T cells |
HEK293T cells |
|
| Merck and IAVI | USA | Replication-competent recombinant vesicular stomatitis virus (VSVΔG)
“V590” Given: Intramuscular |
Development Discontinued Phase 1 |
Operation Warp Speed
HHS-BARDA $38,033,570 |
Vero monkey cells |
Vero monkey cells |
� |
| Shenzhen Geno-immune
Medical Institute |
China | Lentivirus minigenes +
Adult human APC (antigen-presenting cells) “COVID-19/aAPC” Given: Subcutaneous 3 doses (2 weeks apart) |
Phase 1 | � | |
� | |
| Shenzhen Geno-immune
Medical Institute |
China | Lentivirus minigenes +
Adult human CD/T cells (dendritic cells and T cells) “LV-SMENP-DC” Given: Subcutaneous and Intravenous 1 dose |
Phase 1/2 | � | |
� | |
| Vaxart | USA | Replication-deficient
Adenovirus vector “VXA-CoV2-1” plus dsRNA adjuvant Given: Oral 2 doses (4 weeks apart) |
Phase 1 |
HEK293 cells |
HEK293 cells |
|
|
| PROTEIN-BASED VACCINE | |||||||
| Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences | China | Protein vaccine
Recombinant RBD dimer plus adjuvant ”ZF2001” Given: Intramuscular 2 or 3 doses (28 days apart) |
Phase 3 |
HEK293T cells |
CHO hamster cells |
Pseudovirus HEK293T cells |
|
| Clover Biopharmaceuticals, Inc. | China | Protein vaccine
“SCB-2019” plus adjuvant CpG 1018 Given: Intramuscular |
Phase 2/3 | CEPI up to $69.5 Million | cDNA in expression vector; transfect CHO hamster cells
|
CHO hamster cells |
PseudovirusHEK293 cellsRef’d: Nie et al., Emerging Microbes & Infections 24Mar2020Cytopathic effect Vero monkey cellsLiang et al., bioRxiv, 24Sept2020 |
| COVAXX and United Biomedical | USA Taiwan |
Protein vaccine
“UB-612” S1-RBD-protein; Multitope Peptide-Based Vaccine (MVP) Given: Intramuscular |
Phase 2/3 | cDNA in expression vector; transfect CHO hamster cells
|
CHO hamster cells |
Antibody blocked binding to hACE2 HEK293 Guirakhoo et al., bioRxiv, 30Nov2020 |
|
| Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vektor” | Russia | Protein vaccine “EpiVacCorona” chemically synthesized peptide antigens of SARS-CoV-2, conjugated to a carrier protein adsorbed on an aluminum-containing adjuvant Given: Intramuscular2 doses (3 weeks apart) |
Phase 3
Early approval in Russia Oct 2020 |
� |
chemically synthesized peptide antigens |
� | |
| Instituto Finlay de Vacunas | Cuba | Protein vaccine “Finlay-FR-1” (“Soberana 01”) Receptor-binding domain (RBD) SARS-CoV-2 spike + adjuvant Given: Intramuscular2 doses (4 weeks apart) |
Phase 1/2 Phase 1 |
� RBD produced in mammalian cells Garcia-Rivera, MEDICC Review, 30Oct2020 |
� RBD produced in mammalian cells Garcia-Rivera, MEDICC Review, 30Oct2020 |
� | |
| Instituto Finlay de Vacunas | Cuba | Protein vaccine “Finlay-FR-2” (“Soberana 02”) Receptor-binding domain (RBD) SARS-CoV-2 spike chemically bound tetanus toxoid + adjuvant Given: Intramuscular2 doses (4 weeks apart) |
Phase 2 Phase 1 |
� RBD produced in mammalian cells Garcia-Rivera, MEDICC Review, 30Oct2020 |
� RBD produced in mammalian cells Garcia-Rivera, MEDICC Review, 30Oct2020 |
� | |
| John Paul II Medical Research Institute | USA | Recombinant Protein
Perinatal human cells (term umbilical cord and placental) |
Pre-clinical |
|
|
� | |
| Kentucky BioProcessing, Inc. (British American Tobacco) |
USA | Protein vaccine “KBP-201” Plant-expressed RBD Given: Intramuscular2 doses (3 weeks apart) |
Phase 1/2 |
Recombinant DNA sequence for RBD of SARS-CoV-2 |
Plant expression of RBD peptide |
� | |
| Medicago | Canada | Protein on Virus-Like Particle
“CoVLP” Plant-expressed spike protein particle with adjuvant, CpG1018 or AS03 Given: Intramuscular 2 doses (3 weeks apart) |
Phase 2/3 |
Recombinant DNA sequence in Agrobacterium, transformation of plant cells |
Plant expression of protein and VLP |
Pseudovirus HEK293 cells |
|
| Migal Galilee Research Institute | Israel | Protein vaccine
E. coli expressed chimeric S and N proteins Given: Oral |
Pre-clinical | � |
Bacterial production system |
� | |
| Novavax | USA | Protein vaccine
“NVX-CoV2373” Baculovirus expression plus Matrix M adjuvant Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3 | Operation Warp Speed
HHS-BARDA $1,600,434,523 CEPI up to $388 Million |
|
Sf9 insect cells |
Pseudovirus HEK293 cells |
| Sanofi and GSK
Protein Sciences
|
USA
France |
Protein vaccine
Baculovirus expression plus AS03 adjuvant Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3 | Operation Warp Speed
HHS-BARDA $2,072,775,336 total |
Recombinant baculovirus |
Sf9 insect cells |
Pseudovirus HEK293T cells |
| Sorrento | USA | Protein vaccine
“T-VIVA-19” SARS-Cov-2 spike protein S1 domain fused with human IgG-Fc Given: Intramuscular |
Pre-clinical | |
CHO cells |
Antibody ELISA; Neutralization assays Vero monkey cells |
|
| Sorrento | USA | Protein vaccine
“STI-6991” SARS-Cov-2 spike protein expressed on K562 cells |
Pre-clinical | � |
K562 cells |
� | |
| University of Pittsburgh | USA | Protein vaccine
Adenovirus-expressed recombinant proteins “PittCoVacc” Given: Microneedle arrays |
Pre-clinical |
HEK293 cells |
HEK293 cells |
|
|
| University of Queensland and CSL Ltd. | Australia | Protein vaccine
“V451” Recombinant protein with proprietary molecular clamp Given: Intramuscular |
HALTED | CEPI up to $4.5 Million | |
expiCHO hamster cells
|
� |
| Walter Reed Army Institute of Research (WRAIR) / U.S. Army Medical Research and Development Command | USA | Protein vaccine
”SpFN” Spike-Ferritin nanoparticle with ALFQ adjuvant Given: Intramuscular 2-3 doses (4 weeks apart; plus 6 months after initial injection) |
Phase 1 |
Expi293 cells |
Expi293 cells |
Pseudovirus HEK293 cells Virus neutralization Vero monkey cells |
|
| RNA VACCINE | |||||||
| Arcturus Therapeutics | USA | mRNA vaccine
self-transcribing, replicating “LUNAR-CoV19” (“ARCT-021”) in vitro transcription reaction with T7 RNA polymerase from STARR plasmid template LUNAR proprietary lipid nanoparticle encapsulated Given: Intramuscular 1 dose |
Phase 2
|
Sequence designed on computer |
No cells used |
protein test HEK293 Protein expression Hep3b cells Plaque reduction neutralization Vero monkey cells |
|
| CureVac | Germany | mRNA vaccine
non-replicating “CVnCoV” in vitro transcription lipid nanoparticle encapsulated Given: Intramuscular 2 doses (4 weeks apart) |
Phase 3 | CEPI up to $15.3 Million |
Sequence designed on computer |
No cells used |
Protein test Reticulocyte lysate, |
| Imperial College London | UK | mRNA vaccine
Self-amplifying ”LNP-nCoVsaRNA” in vitro transcription lipid nanoparticle encapsulated Given: Intramuscular 2 doses |
Phase 1 |
Expression plasmid HEK293 cells |
No cells used |
Pseudovirus HEK293T cells |
|
| Moderna, Inc.
with National Institutes of Health |
USA | mRNA vaccine
non-replicating “mRNA-1273” T7 RNA polymerase-mediated transcription from DNA plasmid template LNP (lipid nanoparticle) encapsulated Given: Intramuscular 2 doses (4 weeks apart) |
FDA Emergency Use Authorization Approved | Operation Warp Speed
HHS-BARDA $2,479,894,979 total CEPI up to $1 Million |
Sequence designed on computer |
No cells used |
protein test & pseudovirus HEK293 cells Plaque reduction neutralization Vero monkey cells |
| Pfizer and BioNTech | USA
Germany |
mRNA vaccine
non-replicating “BNT-162a1,b1,b2,b3,c2” nucleoside-modified mRNA in vitro transcribed by T7 polymerase from a plasmid DNA template LNP (lipid nanoparticle) encapsulated Given: Intramuscular 2 doses (3 weeks apart) |
FDA Emergency Use Authorization Approved
UK EUA granted
|
Operation Warp Speed
HHS-BARDA $1.95 Billion |
Sequence designed on computer |
No cells used |
protein test & pseudovirus HEK293 cells Neutralization assay Vero monkey cells |
| Providence Therapeutics | Canada | mRNA vaccine
“PTX-COVID19-B” mRNA in vitro transcription from plasmid template using T7 RNA polymerase Given: Intramuscular 2 doses (4 weeks apart) |
Phase 1 |
HEK293T cells used to select mRNA candidate |
No cells used |
Pseudovirus, serum neutralization HEK293T cells Vero monkey cells |
|
| Sanofi Pasteur and
Translate Bio |
USA
France |
mRNA vaccine
non-replicating “MRT5500” synthesized by in vitro transcription employing RNA polymerase with a plasmid DNA template LNP (lipid nanoparticle) encapsulated Given: Intramuscular 2 doses (3 weeks apart) |
Phase 1/2 |
HEK293T cells used to select mRNA candidate |
No cells used Kalnin et al., npj Vaccines 19Apr2021 |
protein test & pseudovirus HEK293 cells |
|
| DNA VACCINE | |||||||
| Genexine | Korea | DNA vaccine
“GX-19” DNA synthesized in vitro, placed in plasmid vector Given: Intramuscular and Electroporation 2 doses (4 weeks apart) |
Phase 1/2 |
Sequence designed on computer |
No cells used |
No cells used
|
|
| Inovio Pharmaceuticals | USA | DNA vaccine
“INO-4800” DNA synthesized in vitro, placed in plasmid vector Given: Intradermal Electroporation 2 doses (4 weeks apart) |
Phase 2/3 | Operation Warp Speed
CEPI up to $22.5 Million |
Sequence designed on computer |
No cells used |
protein test & pseudovirus HEK293 cells |
| Osaka University, AnGes, Takara Bio | Japan | DNA vaccine
“AG0301-COVID19” 2 doses (2 weeks apart) |
Phase 2/3 |
Sequence designed on computer |
No cells used |
Virus neutralization Vero E6 cells monkey cells |
|
| Symvivo Corporation | Canada | DNA vaccine
“bacTRL-spike” Given: Oral, bacteria bind to gut lining 1 dose |
Phase 1 | � |
No cells used |
� | |
| Zydus Cadila | India | DNA vaccine
“ZyCov-D” 3 doses (4 weeks apart) |
Phase 3 |
Sequence designed on computer |
No eukaryotic cells used |
Expression analysis |
|
US Congressman [Rep. Thomas Massie] questions the impartiality of Facebook’s factcheck.org which is supposed to tackle vaccine disinformation as it’s indirectly funded by J&J
US Rep. Thomas Massie reveals that Factcheck.org is funded by the Robert Wood Johnson Foundation which owns $1.8 billion of stock in Johnson & Johnson and is run by a former director of the CDC
The vaccine brought in $3.5 billion in revenue in the first three months of this year, nearly a quarter of its total revenue, Pfizer reported. The vaccine was, far and away, Pfizer’s biggest source of revenue.
On Tuesday, the company announced just how much money the shot is generating.
The vaccine brought in $3.5 billion in revenue in the first three months of this year, nearly a quarter of its total revenue, Pfizer reported. The vaccine was, far and away, Pfizer’s biggest source of revenue.
The company did not disclose the profits it derived from the vaccine, but it reiterated its previous prediction that its profit margins on the vaccine would be in the high 20 percent range. That would translate into roughly $900 million in pretax vaccine profits in the first quarter.
https://www.nytimes.com/2021/05/04/business/pfizer-covid-vaccine-profits.html
Danish authorities have opted for a more cautious path, even though Reuters reported that excluding J&J’s shot could significantly delay the country’s vaccination efforts.
Danish drug officials last month abandoned the use of AstraZeneca’s Covid-19 vaccine, also citing the risk of blood clots. In March, Denmark became the first country in the world to temporarily suspend the AstraZeneca shot, but unlike its European neighbors, the country made that suspension permanent.
https://www.rt.com/news/522790-denmark-cancels-johnson-vaccine/
Johnson & Johnson privately reached out to Covid-19 vaccine rivals to ask them to join an effort to study the risks of blood clots and speak with one voice about safety, but Pfizer Inc. and Moderna Inc. declined.
A Covid vaccination site shuttered its doors early after 13 patients suffered bad reactions to their shots. The mass vaccination event at Dick’s Sporting Goods Part in Commerce Field, Colorado, was halted on Wednesday, with two patients taken to hospital for further evaluation.
Johnson & Johnson (J&J) has expanded Phase IIa clinical trial of Covid-19 vaccine candidate to include adolescent subjects aged 12 to 17 years.
https://www.clinicaltrialsarena.com/news/johnson-vaccine-trial-adolescents/